SCHEMBL30028494

SCHEMBL30028494

CC(C)(C)OC(=O)N1CCC[C@@H](Oc2cccc(C(F)(F)F)c2)C1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.52
CHEK2 O96017 1/20 0.49
ABHD6 Q9BV23 2/20 0.47
MGLL Q99685 1/20 0.47
EPHX2 P34913 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
GPR119 Q8TDV5 1/20 0.46
SLC6A2 P23975 1/20 0.45
SLC6A4 P31645 1/20 0.45
SLC6A3 Q01959 1/20 0.45
PDE4B Q07343 1/20 0.45
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
FFAR1 O14842 2/20 0.44
P2RX3 P56373 1/20 0.44
P2RX2 Q9UBL9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9900709 0.94 USP30 (0.56) USP30ABHD6MGLLEPHX2MEN1
SCHEMBL19406085 0.89 ABHD6 (0.52) USP30ABHD6MGLLEPHX2MEN1
SCHEMBL6036543 0.87 EPHX2 (0.57) USP30ABHD6MGLLEPHX2MEN1
SCHEMBL29280846 0.87 CHEK2 (0.54) USP30CHEK2GPR119PDE4BMAPT
SCHEMBL30842586 0.87 CHEK2 (0.54) USP30CHEK2GPR119PDE4BMAPT
SCHEMBL29280843 0.87 CHEK2 (0.54) USP30CHEK2GPR119PDE4BMAPT
SCHEMBL28826952 0.86 CHEK2 (0.55) USP30CHEK2GPR119PDE4B
SCHEMBL1897524 0.85 USP30 (0.51) USP30CHEK2MEN1KMT2AGPR119
SCHEMBL1899757 0.85 USP30 (0.51) USP30CHEK2MEN1KMT2AGPR119
SCHEMBL1897521 0.85 USP30 (0.51) USP30CHEK2MEN1KMT2AGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220402869-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402869-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 USP30 2069/4885CHEK2 870/4885ABHD6 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.